Orally administered endoxifen is a new therapeutic agent for breast cancer. - Wikidata - awgldk - TriplyDB

Orally administered endoxifen is a new therapeutic agent for breast cancer.

Orally administered endoxifen is a new therapeutic agent for breast cancer.

http://www.wikidata.org/entity/Q34091195

about

Identification of a novel Calotropis procera protein that can suppress tumor growth in breast cancer through the suppression of NF-κB pathway The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Characterization of the isomeric configuration and impurities of (Z)-endoxifen by 2D NMR, high resolution LC⬜MS, and quantitative HPLC analysis Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects.The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats.Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies.Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer.CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer.Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation.Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer.Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs.Application of genotype-guided cancer therapy in solid tumors.Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem.The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.Orally administered endoxifen inhibits tumor growth in melanoma-bearing mice.Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts.Refined protocols of tamoxifen injection for inducible DNA recombination in mouse astroglia.

P2860

Q28484477-895C32D0-1090-488B-BF9E-7653A81BBD18 Q28546094-CE2708BA-8381-4357-BF69-D23DE5F59993 Q30400967-8B1DF89F-628D-416B-95B5-0CA83BC953B2 Q30668728-35D04A1E-6B5B-41BC-B477-9BD21CF0D3D8 Q34146176-58F64477-9881-495D-B2B2-0B7BF7BF6F4D Q34205869-55DE36C8-5568-4CC7-842E-49D30F484342 Q34253146-57B7ED93-C83F-4BEE-9E2E-BC8DA5CA3A50 Q35129546-5CE69CC9-9A8D-4C2C-97E4-550003654314 Q35915042-16F2BB1F-D45B-4D36-AFBE-0FCC09871208 Q36644642-06B31E62-D565-41BC-9CF9-49E59CC2A266 Q36950502-FCF3EE97-34CA-4601-9B3F-ACEC239D798E Q37014147-57C325BD-9BE7-4A13-BF73-E05FB907FCDD Q38017920-9097DBAD-0A0F-4498-BDEB-64E28FA3038C Q38107969-4609F188-CD89-4699-A336-14EBC8FB8715 Q38170457-CAEBFAFB-3766-4BF3-81CC-8108F159E56D Q42755954-5698ED24-848F-4589-81CE-E200ADB46A4E Q45905355-D1DF3857-A027-4BE8-AEF4-D0605334063A Q47122154-46ECC513-5999-4953-8E59-4F55229D9018 Q50625597-0BD53006-B5CA-4928-8DDF-9A51BD162E1B Q53110628-07BBA081-AD00-43C5-8167-C92C3A47A858 Q55118066-E15BC2CF-FDCD-4DA5-A49E-344E22DBEABB

P2860

Orally administered endoxifen is a new therapeutic agent for breast cancer.

http://www.wikidata.org/entity/Q34091195

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Orally administered endoxifen is a new therapeutic agent for breast cancer.

@ast

Orally administered endoxifen is a new therapeutic agent for breast cancer.

@en

Orally administered endoxifen is a new therapeutic agent for breast cancer.

@nl

type

label

Orally administered endoxifen is a new therapeutic agent for breast cancer.

@ast

Orally administered endoxifen is a new therapeutic agent for breast cancer.

@en

Orally administered endoxifen is a new therapeutic agent for breast cancer.

@nl

prefLabel

Orally administered endoxifen is a new therapeutic agent for breast cancer.

@ast

Orally administered endoxifen is a new therapeutic agent for breast cancer.

@en

Orally administered endoxifen is a new therapeutic agent for breast cancer.

@nl

P1433

Q34091195-C84C9D8C-D91D-4FE5-AB84-E5B0EC70D1DF

P1476

Q34091195-2529A80D-37F6-4DFC-B8C3-8EEA51EBBDE7

P2093

Q34091195-03960670-143C-4FBB-A1A3-803E72E95784

Q34091195-1B4F1CD8-6966-4364-AEB5-75A3E042BAF3

Q34091195-1F62C719-04B4-4B4D-B397-E3A8BC6A5FFC

Q34091195-2CD301D8-B63B-4A85-B8E2-49ED16D6639D

Q34091195-BA3DAB51-408C-45DA-8B5C-5A332C9514E4

P2860

Q34091195-38FF3D86-1C5D-423C-98F5-0D8ECF60A716

Q34091195-3A123FB6-1E79-4699-8A6D-6F20D10A5128

Q34091195-53DFB126-875A-4198-A527-A3D037AFB8B9

Q34091195-56E7DBA5-68E4-4C03-A81B-0A4BB5F54C58

Q34091195-700772AB-FB8C-4F68-B1EE-7A4269957E0B

Q34091195-730F65CF-82B2-4E8B-9848-E8FFAAD2D32B

Q34091195-75CAF7F6-1404-4D27-A442-834121DB2B6B

Q34091195-84330756-85C5-4075-9EE9-0DE7BC8CB155

Q34091195-93CA9928-D0A0-4E0E-82F3-773435050BD7

Q34091195-9686BCE3-BD4F-4369-A3E9-545A5657EA10

P2888

Q34091195-87B4DAEA-75A1-4706-BB69-E54F7F9D2B9D

P304

Q34091195-09C78BE6-1B07-4151-B8C9-92EB9F175469

P31

Q34091195-E8B13C68-7974-4B5B-A782-00223508201E

P356

Q34091195-69B113DF-B848-4249-BD4D-29E9F2ADFAB5

P407

Q34091195-D8B3149B-038B-41CA-ABE8-EE3A8AFB0A7F

P433

Q34091195-EBC926F2-F3AC-48E3-91C7-CAE2E47087C3

P478

Q34091195-72ED3E9F-61F6-4E5E-A02E-E4565B424E74

P577

Q34091195-9F508B90-D7E3-46DF-9CAF-97E481B0C0F8

P6179

Q34091195-09605A68-B8DF-407C-AFF2-B960AFA510C1

P698

Q34091195-77AA6F28-388E-4513-A087-D8B2CE526202

P356

S10549-009-0704-7

P1433

Breast Cancer Research and Treatment

P1476

Orally administered endoxifen is a new therapeutic agent for breast cancer.

@en

P2093

Ateeq Ahmad

http://www.w3.org/2001/XMLSchema#string

Imran Ahmad

http://www.w3.org/2001/XMLSchema#string

Moghis U Ahmad

http://www.w3.org/2001/XMLSchema#string

Saifuddin Sheikh

http://www.w3.org/2001/XMLSchema#string

Shoukath M Ali

http://www.w3.org/2001/XMLSchema#string

P2860

Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force

The pharmacology and clinical uses of tamoxifen

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

The NCI60 human tumour cell line anticancer drug screen

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

P2888

s10549-009-0704-7

P304

579-584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-009-0704-7

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1003317503

http://www.w3.org/2001/XMLSchema#string

P698

20052538

http://www.w3.org/2001/XMLSchema#string